SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Syndax’s Revuforj Wins 2026 Prix Galien USA Award

Syndax said Revuforj received the Prix Galien USA award for Best Product for Rare/Orphan Diseases. The company describes it as the first and only menin inhibitor approved for adults and children one year and older with R/R NPM1m AML and KMT2A-translocated acute leukemia.

SNDX

Related stories